The estimated Net Worth of Ludwig Hantson is at least $51.3 Million dollars as of 31 December 2018. Ludwig Hantson owns over 3,244 units of Alexion Pharmaceuticals stock worth over $27,589,424 and over the last 14 years he sold ALXN stock worth over $4,748,873. In addition, he makes $18,948,000 as Chief Executive Officer and Director at Alexion Pharmaceuticals.
Ludwig has made over 7 trades of the Alexion Pharmaceuticals stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 3,244 units of ALXN stock worth $310,937 on 31 December 2018.
The largest trade he's ever made was exercising 36,059 units of Alexion Pharmaceuticals stock on 25 September 2012 worth over $1,497,891. On average, Ludwig trades about 2,279 units every 52 days since 2010. As of 31 December 2018 he still owns at least 150,696 units of Alexion Pharmaceuticals stock.
You can see the complete history of Ludwig Hantson stock trades at the bottom of the page.
Dr. Ludwig N. Hantson Ph.D. serves as Chief Executive Officer, Director of the Company. Dr. Hantson became Chief Executive Officer of Alexion on March 27, 2017. Prior to joining Alexion, Dr. Hantson was President and Chief Executive Officer of Baxalta Incorporated. He led Baxalta’s successful spin-off as a public company from Baxter International Inc. in July 2015 where he was President of Baxter BioScience. He joined Baxter in May 2010 and established the BioScience division as an innovative specialty and rare disease company with a pipeline of 25 new product candidates, and 13 product launches. Prior to Baxter, from 2001 to 2010, Dr. Hantson held several leadership roles at Novartis AG, including CEO of Pharma North America, CEO of Europe, and President of Pharma Canada. Prior to Novartis, Dr. Hantson spent 13 years with Johnson & Johnson in roles of increasing responsibility in marketing and research and development. Dr. Hantson received his Ph.D. in motor rehabilitation and physical therapy, Master’s degree in physical education, and a certification in high secondary education, all from the University of Louvain in Belgium.
As the Chief Executive Officer and Director of Alexion Pharmaceuticals, the total compensation of Ludwig Hantson at Alexion Pharmaceuticals is $18,948,000. There are no executives at Alexion Pharmaceuticals getting paid more.
Ludwig Hantson is 57, he's been the Chief Executive Officer and Director of Alexion Pharmaceuticals since 2017. There are 10 older and 8 younger executives at Alexion Pharmaceuticals. The oldest executive at Alexion Pharmaceuticals Inc. is John Mollen, 69, who is the Independent Director.
Ludwig's mailing address filed with the SEC is Campus Drive, Marlborough, Middlesex County, Massachusetts, 01752, United States.
Over the last 21 years, insiders at Alexion Pharmaceuticals have traded over $451,742,532 worth of Alexion Pharmaceuticals stock and bought 2,576,434 units worth $277,855,180 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Leonard Bell, and Paul A Friedman. On average, Alexion Pharmaceuticals executives and independent directors trade stock every 9 days with the average trade being worth of $3,460,578. The most recent stock trade was executed by Daniel Bazarko on 17 December 2020, trading 24,066 units of ALXN stock currently worth $2,816,685.
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.
Alexion Pharmaceuticals executives and other stock owners filed with the SEC include: